SciVision Biotech Inc Cash Flow Conversion Efficiency
SciVision Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, SciVision Biotech Inc (1786) has a cash flow conversion efficiency ratio of 0.026x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$48.51 Million ≈ $1.53 Million USD) by net assets (NT$1.86 Billion ≈ $58.58 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SciVision Biotech Inc (2009–2025)
Cash flow conversion efficiency of SciVision Biotech Inc from 2009 to 2025. This chart illustrates how SciVision Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest SciVision Biotech Inc stock price today for real-time trading data and today's change.
SciVision Biotech Inc Cash Flow Conversion Ratio Explained
SciVision Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SciVision Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SciVision Biotech Inc ranked by their cash flow conversion efficiency. Also see market cap of SciVision Biotech Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CAB Cakaran Corporation Bhd
KLSE:7174
|
0.032x |
|
Top Union Electronics
TWO:6266
|
0.064x |
|
Lemonsoft Oyj
HE:LEMON
|
0.093x |
|
Tiong Nam Logistics Holdings Bhd
KLSE:8397
|
0.045x |
|
PT Indonesia Kendaraan Terminal Tbk
JK:IPCC
|
0.066x |
|
Nova Klúbburinn hf.
IC:NOVA
|
N/A |
|
Wonder Electricals Limited
NSE:WEL
|
0.133x |
|
Innowireless Co. Ltd
KQ:073490
|
-0.014x |
Annual Cash Flow Conversion Efficiency for SciVision Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of SciVision Biotech Inc from 2009 to 2025. Review 1786 cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.98 Billion ≈ $62.39 Million |
NT$123.99 Million ≈ $3.91 Million |
0.063x | -55.99% |
| 2024-12-31 | NT$1.90 Billion ≈ $59.77 Million |
NT$269.87 Million ≈ $8.50 Million |
0.142x | -14.94% |
| 2023-12-31 | NT$1.63 Billion ≈ $51.24 Million |
NT$272.01 Million ≈ $8.57 Million |
0.167x | +41.79% |
| 2022-12-31 | NT$1.51 Billion ≈ $47.60 Million |
NT$178.21 Million ≈ $5.61 Million |
0.118x | +73.60% |
| 2021-12-31 | NT$1.45 Billion ≈ $45.68 Million |
NT$98.51 Million ≈ $3.10 Million |
0.068x | -24.57% |
| 2020-12-31 | NT$1.40 Billion ≈ $44.24 Million |
NT$126.47 Million ≈ $3.98 Million |
0.090x | -40.04% |
| 2019-12-31 | NT$1.36 Billion ≈ $42.87 Million |
NT$204.40 Million ≈ $6.44 Million |
0.150x | +44.98% |
| 2018-12-31 | NT$1.08 Billion ≈ $33.97 Million |
NT$111.70 Million ≈ $3.52 Million |
0.104x | +492.97% |
| 2017-12-31 | NT$914.45 Million ≈ $28.81 Million |
NT$15.98 Million ≈ $503.39K |
0.017x | -59.19% |
| 2016-12-31 | NT$894.21 Million ≈ $28.17 Million |
NT$38.29 Million ≈ $1.21 Million |
0.043x | -18.46% |
| 2015-12-31 | NT$948.60 Million ≈ $29.89 Million |
NT$49.81 Million ≈ $1.57 Million |
0.053x | +2800.57% |
| 2014-12-31 | NT$1.02 Billion ≈ $32.23 Million |
NT$1.85 Million ≈ $58.35K |
0.002x | -94.74% |
| 2013-12-31 | NT$1.08 Billion ≈ $34.15 Million |
NT$37.27 Million ≈ $1.17 Million |
0.034x | -71.56% |
| 2012-12-31 | NT$425.98 Million ≈ $13.42 Million |
NT$51.52 Million ≈ $1.62 Million |
0.121x | +18.47% |
| 2011-12-31 | NT$363.70 Million ≈ $11.46 Million |
NT$37.13 Million ≈ $1.17 Million |
0.102x | +66.58% |
| 2010-12-31 | NT$111.73 Million ≈ $3.52 Million |
NT$6.85 Million ≈ $215.72K |
0.061x | +114.28% |
| 2009-12-31 | NT$84.09 Million ≈ $2.65 Million |
NT$-36.09 Million ≈ $-1.14 Million |
-0.429x | -- |
About SciVision Biotech Inc
SciVision Biotech Inc. develops and manufactures medical-grade hyaluronic acid products in Taiwan. The company offers synovial fluid supplements, facial dermal implants, absorbable adhesion barriers, and intravesical instillation products. It also involved in international trade; wholesale of medical equipment and cosmetics; and provides management advisory services. SciVision Biotech Inc. was fo… Read more